Novo Nordisk Surges to 150th in Trading Volume with $646 Million Turnover

On May 27, 2025, Novo Nordisk (NVO) saw a significant increase in trading volume, with a turnover of $646 million, marking a 47.77% rise from the previous day. This surge placed Novo Nordisk at the 150th position in terms of trading volume for the day. The stock price of Novo Nordisk also rose by 4.59%.

The recent delay in the implementation of a 50% tariff on European Union imports by President Trump has positively impacted Novo Nordisk's stock. The tariff, initially set to begin on June 1, has been postponed until July 9. This delay is beneficial for Novo Nordisk, as a significant portion of its GLP-1 drugs are manufactured in Denmark and could have been subject to the tariff. The delay provides an opportunity for negotiations that could potentially lower or remove the tariffs entirely, which would be favorable for the company's stock.

Novo Nordisk has been strategically investing in expanding its manufacturing capacity, particularly in the U.S., to meet the growing demand for its diabetes and obesity care products. The company announced plans to spend $4.1 billion on U.S. production facilities for Ozempic and Wegovy, indicating a strong commitment to the U.S. market. This investment is crucial as 25% of Novo Nordisk's assets are located in the U.S., and the company aims to capitalize on the rising popularity of GLP-1 drugs.

Analysts have given Novo Nordisk a consensus rating of "Moderate Buy" with a target price of $135.00. The company's earnings estimates for the next fiscal year indicate a 20.9% increase from the previous year, reflecting positive market sentiment and expectations for future growth. Additionally, the average rating for NVO stock is "Strong Buy," with a 12-month stock price forecast of $128.00, representing an 81.72% increase from current levels.